<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109470</url>
  </required_header>
  <id_info>
    <org_study_id>PRC-03-2012</org_study_id>
    <nct_id>NCT03109470</nct_id>
  </id_info>
  <brief_title>The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience</brief_title>
  <official_title>The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pope Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pope Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this
      study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients
      who were treated with Tocilizumab to require treatment with another biologic medication.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient enrollment potential
  </why_stopped>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Biologic Treatment</measure>
    <time_frame>2 years</time_frame>
    <description>To describe the rate of requiring biologic treatment over 2 years following completion of the FUNCTION study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment after completion of FUNCTION study</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the type of RA treatment regimen used by the treating physician upon completion of the FUNCTION study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of requiring treatment intensification</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the rate of requiring treatment intensification with a traditional DMARD(s) completion of the FUNCTION study. The durability of response after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional status</measure>
    <time_frame>2 years</time_frame>
    <description>The change in patient-reported functional status over 2 years after tocilizumab withdrawal or maintaining Mtx or changing DMARD(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work productivity</measure>
    <time_frame>2 years</time_frame>
    <description>To determine work productivity over 2 years after completion of the FUNCTION study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Utilization</measure>
    <time_frame>2 years</time_frame>
    <description>To determine health-care utilization over 2 years after completion of the FUNCTION study</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients withdrawing first-line tocilizumab and/or methotrexate therapy due to therapeutic
        response during the FUNCTION (WA19926) study that have agreed to provide informed consent
        will be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed 2 years in the FUNCTION (WA19926) trial

          -  Patient has provided written informed consent and is willing to comply with the
             requirements of this study protocol

        Exclusion Criteria:

          -  Requirement for immediate treatment with a biologic therapy following completion of
             the FUNCTION (WA19926) trial as per treating physician judgement.

          -  Presence of any condition that, in the opinion of the treating physician, prohibits
             the patient from participating in the study or obscures the assessment of the
             treatment of RA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Pope, MD, MPH, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pope Research Corp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John S Sampalis, BSc, BA, MSc, PHD, FACE</last_name>
    <role>Principal Investigator</role>
    <affiliation>JSS Medical Research Inc.</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <keyword>Early Rheumatoid Arthritis</keyword>
  <keyword>Observational</keyword>
  <keyword>Canadian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

